CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Prolonged MMX® mesalazine therapy in patients with acute, mild-to-moderate ulcerative colitis who fail initial mesalazine treatment may prevent a requirement for therapeutic escalation
DOI 10.1055/s-0030-1263696
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Kamm, R Panaccione, K Barrett, D Solomon, B Abhyankar, K Lees
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: MMX® mesalazine (Mezavant®, Shire Pharmaceuticals Inc., USA; MMX; Cosmo Technologies Ltd, Ireland) has been observed to successfully induce remission in patients with mild-to-moderate ulcerative colitis (UC) in two, phase III, placebo-controlled (parent) studies by Lichtenstein et al. (SPD476–301) and Kamm et al. (SPD476–302). Objectives: We examine the proportion of patients who did not achieve remiss…
Zitieren
Zitierempfehlung
M Kamm, R Panaccione, K Barrett, D Solomon, B Abhyankar, K Lees (2010) Prolonged MMX® mesalazine therapy in patients with acute, mild-to-moderate ulcerative colitis who fail initial mesalazine treatment may prevent a requirement for therapeutic escalation. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0030-1263696
Mit CareLit weiterarbeiten